Scarica l'app Stockscreener
2.74
3.86%
-0.11
Dopo l'orario di chiusura:
2.67
-0.07
-2.55%
Silexion Therapeutics Corp Borsa (SLXN) Ultime notizie
Price to earnings forward of Silexion Therapeutics Corp – NASDAQ:SLXN - TradingView
Enterprise value to EBITDA forward of Silexion Therapeutics Corp – BOATS:SLXN - TradingView
Silexion Therapeutics (SLXN) price target decreased by 33.33% to 6.12 - MSN
SLXN Q1 2026 Earnings: EPS Beat Highlights Narrower-than-Expected Loss Amid Development StageFinancial Summary - dars.gov.et
Price to sales forward of Silexion Therapeutics Corp – BOATS:SLXNW - TradingView
Price to earnings forward of Silexion Therapeutics Corp – BOATS:SLXNW - TradingView
Enterprise value to revenue forward of Silexion Therapeutics Corp – BOATS:SLXNW - TradingView
Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer - Sahm
Silexion Therapeutics Warrants (SLXNW) Hold Flat at $0.03 as Range TightensComposite Profile - dars.gov.et
Form 13D/A Silexion Therapeutics Corp For: 23 June By Investing.com - Investing.com Australia
Silexion Therapeutics Says Germany Approves Phase 2/3 Trial of SIL204 in Pancreatic Cancer - marketscreener.com
Silexion Therapeutics Receives BfArM Approval to Initiate Phase 2/3 SIL204 Trial in Germany - Quiver Quantitative
[EFFECT] Silexion Therapeutics Corp SEC Filing - Stock Titan
SLXN Q1 2026 Earnings: Solid EPS Beat Highlights Cost Discipline Amid Pre-Revenue StageEarnings Risk Report - dars.gov.et
Silexion Therapeutics (SLXN) Slides 5.86% as Shares Approach Key Support at $2.59Oversold Bounce Ideas - dars.gov.et
Silexion Therapeutics Corp (SLXN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Silexion Therapeutics Corp (SLXN) Institutional Confidence - TradingKey
Silexion Therapeutics Corp (SLXN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Silexion Therapeutics Corp (SLXN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Silexion Therapeutics Corp (SLXN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Silexion (NASDAQ: SLXN) registers resale of 859,609 shares including warrants/conversions - Stock Titan
Silexion Therapeutics Corp (SLXN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Silexion Therapeutics Corp (SLXN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Silexion Therapeutics Corp (SLXN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Silexion Therapeutics Corp (SLXNW) Institutional Confidence - TradingKey
Silexion Therapeutics Corp (SLXNW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Silexion Therapeutics Corp (SLXNW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Silexion Therapeutics Corp (SLXNW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Silexion Therapeutics Corp (SLXNW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Silexion Therapeutics Corp (SLXNW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Silexion Therapeutics Corp (SLXNW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Silexion Therapeutics Corp - TradingKey
Silexion Therapeutics Corp (SLXNW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Silexion Therapeutics Corp (SLXN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Silexion (NASDAQ: SLXN) puts big share increase and warrant vote to holders - Stock Titan
Silexion Therapeutics to Attend BIO International Convention 2026 - GlobeNewswire
Biotech Silexion opens one-on-one meetings at BIO 2026 - Stock Titan
SLXN Q1 2026 Earnings: Narrowed Loss Beats Estimates with 35.4% EPS SurpriseAnalyst Drop Coverage - newsline.com
Silexion Therapeutics (NASDAQ: SLXN) registers up to 859,609 resale shares - Stock Titan
Silexion Therapeutics Corp Warrant (SLXNW) Holds Steady at $0.03 Amid Minimal Trading ActivityNegative Gamma - dars.gov.et
Silexion Therapeutics Warrants (SLXNW) Plunge 33% as Support at $0.03 Faces TestParabolic SAR - newsline.com
Silexion Therapeutics Corp Ord Stock Short Interest Falls to 43.76% - Quiver Quantitative
SLXN Q1 2026 Earnings: Narrowed Loss Per Share Surprises, Stock GainsCapex Guidance - newsline.com
Number of shareholders of Silexion Therapeutics Corp – NASDAQ:SLXN - TradingView
Silexion (SLXN) awards CSO 6,000 RSUs after reverse share split - Stock Titan
[Form 4] Silexion Therapeutics Corp Insider Trading Activity - Stock Titan
Silexion (SLXN) CEO granted 10,000 shares; holdings rise to 16,547 - Stock Titan
Silexion Therapeutics Corp (SLXN) Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline ProgressesGross Profit Margin - newsline.com
Number of shareholders of Silexion Therapeutics Corp – NASDAQ:SLXNW - TradingView
Silexion (SLXN) asks shareholders to OK 399,020 warrants and a capital increase - Stock Titan
Silexion Stock Just Split 1-for-10. The Real Test Starts Now - Bez Kabli
Silexion Therapeutics Implements 1-for-10 Reverse Share Split - The Globe and Mail
Moringa (SLXN) discloses 1,382,346-share Silexion stake and contests note issuances - Stock Titan
- newsline.com
Silexion Therapeutics Corp Files Form 8-K: NASDAQ Listing, Company Details, and Warrant Information - Minichart
Silexion Therapeutics (SLXN) completes 1-for-10 reverse split, adjusts warrant terms - Stock Titan
SLXN Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost DisciplinePreliminary Results - thelegaladvocate.com
Silexion Therapeutics announces 1-for-10 reverse share split - MSN
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):